Celltrion Extends Remsima SC Indications
Subcutaneous Infliximab Gets Nod Covering IBD And Ankylosing Spondylitis
Executive Summary
Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.
You may also be interested in...
Celltrion Opens Up Canadian Market For Remsima SC
Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.
Canada Approves Celltrion’s Remsima SC Biosimilar
Health Canada has approved Celltrion’s subcutaneous version of Remsima for rheumatoid arthritis, as Celltrion plans to expand indications for the infliximab biosimilar to allow it to also treat inflammatory bowel disease. The company has also established an offshoot in Canada that will allow it to sell Remsima SC directly.
Celltrion Partners With Intract Pharma For Oral Infliximab
South Korea’s Celltrion has partnered with oral drug delivery specialist Intract Pharma for the formulation of oral infliximab for the treatment of inflammatory bowel disease. Celltrion has also reported year-on-year and quarter-on-quarter growth in sales, along with plans to grow in the US market.